

**PRACTICAL
APPROACHES
TO
NON-SMALL CELL
LUNG CANCER
MANAGEMENT
IN THE ERA OF
PERSONALIZED
THERAPY**



Wednesday, 6 July 2011
12.15 – 14.15
Plenary Hall

This presentation was selected by the 14th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 14th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.

PRACTICAL APPROACHES TO NON-SMALL CELL LUNG CANCER MANAGEMENT IN THE ERA OF PERSONALIZED THERAPY

FACULTY

Chair

Román Pérez-Soler, MD

Montefiore Medical Center
Bronx, New York, United States

Faculty

Luis Paz-Ares, MD, PhD

Hospital Universitario Virgen del Rocío
Seville, Spain

Martin Reck, MD, PhD

Hospital Grosshansdorf
Grosshansdorf, Germany

Mark A. Socinski, MD

University of North Carolina
Chapel Hill, North Carolina
United States

Jean-Charles Soria, MD, PhD

Gustave Roussy Institute
Villejuif, France

AGENDA

- 12.30 Welcome and introduction**
Román Pérez-Soler, MD
- 12.40 Defining the unmet needs in non-small cell lung cancer (NSCLC)**
Jean-Charles Soria, MD, PhD
- 12.55 Clinical opinion poll**
- 13.00 Interactive clinical case— Personalizing first-line treatment in the absence of mutations**
Martin Reck, MD, PhD
- 13.30 Clinical opinion poll**
- 13.35 Interactive clinical case— Incorporating EGFR mutation status into first-line therapy selection**
Luis Paz-Ares, MD, PhD
- 13.50 Clinical opinion poll**
- 13.55 Interactive clinical case— Therapeutic decision making in the second-line**
Mark A. Socinski, MD
- 14.10 Ask the experts**
All Faculty, moderated by Román Pérez-Soler, MD
- 14.15 Adjourn**

Register online at www.prIMEoncology.org/WorldLung2011

Wednesday, 6 July 2011
12.15 – 14.15

Lunch will be available for pickup
from 12.15 – 12.30

Amsterdam RAI
Plenary Room
Europaplein 22
1078 GZ Amsterdam
The Netherlands

TARGET AUDIENCE

Practical Approaches to Non-Small Cell Lung Cancer Management in the Era of Personalized Therapy is specifically designed for medical oncologists and other healthcare professionals involved and/or interested in the management of patients with lung cancer.

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Define the clinical, histologic, and molecular factors that guide clinicians in selecting therapy for patients with NSCLC
- Outline appropriate treatment regimens for patients with NSCLC, focusing on how best to tailor therapeutic choices to patient characteristics such as tissue histology, presence or absence of molecular markers, and comorbidities
- Analyze available and emerging treatment options in advanced NSCLC, including maintenance therapy and second-line therapy and beyond
- Identify areas of uncertainty or controversy requiring further clarification regarding the use of patient and disease characteristics as guides for treatment selection at various stages of disease progression in the management of NSCLC

SPONSORSHIP This activity is sponsored by prIME Oncology.



CONTINUING EDUCATION

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. prIME Oncology designates this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

SUPPORT

Support for this activity has been provided by an unrestricted educational grant from F. Hoffmann-La Roche Ltd.



FEE INFORMATION:

There is no fee for this activity and preregistration is not required; however, space is limited.

DISCLOSURE OF UNLABELED USE OF AGENTS

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is sponsored
by prIME Oncology.



EU Office
prIME Oncology

Scheveningseweg 56G
2517 KW The Hague
The Netherlands

tel + 31.70.3067.190
fax + 31.70.3067.199

www.prIMEoncology.org

Support for this activity has been provided
by an unrestricted educational grant from
F. Hoffmann-La Roche Ltd.

